Care of Patients with Liver Disease during the COVID-19 Pandemic
Summary of EASL-ESCMID Position Paper
The European Association for the Study of the Liver (EASL) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published a Position Paper on the ‘Care of patients with liver disease during the COVID-19 pandemic’ to help healthcare providers when reallocating resources to manage the care of people with liver disease and those who have had liver transplants.
The world is still learning about the impact of SARS- CoV-2 (the virus that causes COVID-19) on liver diseases, and until we have evidence to guide decisions about care, the expert opinion of EASL-ESCMID is important.
How COVID-19 may impact your care
We have produced a lay summary of the Position Paper to help non-medical people understand the important content.
Written by Martine Walmsley (PSC Support Chair/EASL PPHC) with Maria Buti (EASL PPHC Chair), the lay summary is endorsed by EASL and covers:
- How healthcare providers are minimising COVID-19 transmission
- What changes to expect in care during the pandemic
- What to expect if you get COVID-19
- Prioritisation of patients for some tests and procedures
Patient Organisation Toolkit
This lay summary was written to support a COVID-19 Toolkit for liver disease patient organisations across Europe, developed by Martine Walmsley and José Willemse, board members of the ERN RARE-LIVER, thanks to a non-financial grant from RPP Group.
The Toolkit has been sent to patient organisation members of the ERN RARE-LIVER and contains:
- the lay summary of the EASL-ESCMID Position Paper on the ‘Care of patients with liver disease during the COVID-19 pandemic'.
- tips and information to:
- help patient organisations communicate effectively about COVID-19;
- empower patient organisations, especially small, rare disease associations, to advocate for appropriate healthcare services for their rare liver disease communities during and after the COVID-19 pandemic.